Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Lokhorst, Henk M., Plesner, Torben, Laubach, Jacob P., Nahi, Hareth, Gimsing, Peter, Hansson, Markus, Minnema, Monique C., Lassen, Ulrik, Krejcik, Jakub, Palumbo, Antonio, van de Donk, Niels W.C.J., Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa M., Wang, Jianping, Sasser, A. Kate, Losic, Nedjad, Lisby, Steen, Basse, Linda, Brun, Nikolai, Richardson, Paul G.·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1506348

Cited by (1,000)

Items 701–800 of 1,000

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
Praful Kumar Ravi, Shaji Kunnathu Kumar, Wilson I. Gonsalves, Francis K. Buadi, Martha Q. Lacy, Ronald S. Go, Angela A. Dispenzieri, Prashant Kapoor, John Anthony Lust, David Dingli et al. · 2017 · Blood Cancer Journal
In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review
Rimke Oostvogels, Simone M. Uniken Venema, Moniek A. de Witte, Reinier A P Raymakers, Jurgen H. E. Kuball, Nicolaus Martin Kröger, Monique C. Minnema · 2017 · Bone Marrow Transplantation
Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost
Kenshi Suzuki · 2020 · International Journal of Hematology
CAR T cells for other pediatric non–B-cell hematologic malignancies
Adam J. Lamble, Rebecca Alice Gardner · 2020 · Hematology
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group
Federico Vozella, A. Siniscalchi, M. Rizzo, Tommaso Zà, Giusy Antolino, Ugo Coppetelli, Alfonso Piciocchi, A Andriani, Ombretta Annibali, Luca De Rosa et al. · 2021 · Annals of Hematology
The molecular biology of multiple myeloma
Wee Joo Chng, Peter Leif Bergsagel · 2019 · Wiley eBooks
Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management
Akram N. Salah, Amr Hosny Hashem, Mohamed Bakr Zaki, Ahmed I. Abulsoud, Asmaa M. Atta, Wagiha S. Elkalla, Hebatallah Ahmed Mohamed Moustafa, Walaa A. El‐Dakroury, Fatma Sa’eed El-Tokhy, Jasmine A. ElBoghdady et al. · 2025 · Journal of Biochemical and Molecular Toxicology
Breaking the cycle: immune complexes, complement activation, and novel immunotherapies in lupus nephritis
Cuiting Dong, Ming‐Shiou Wu, Haonan Liu, Kunpeng Yang, Shuang Ma, Yan Guo, Yue‐Jiao Lan, Xiaodan Lu · 2025 · Frontiers in Immunology
Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies
Xiang Zhou, Johannes Moritz Waldschmidt, Hermann Einsele · 2025 · Blood Reviews
Sequencing of nontransplant treatments in multiple myeloma patients with active disease
Andrew Jenho Yee, Noopur S Raje · 2016 · Hematology
Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma
Rebecca J. Brownlie, Ruth Kennedy, Erica Wilson, Maja Milanovic, Claire Taylor, Dapeng Wang, John R. Davies, Heather Elizabeth Owston, Emma J. Adams, Sophie Stephenson et al. · 2023 · Blood Advances
Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
Antonio Giovanni Solimando, Markus Krebs, Vanessa Desantis, Donatello Marziliano, Ingrid Catalina Caradonna, Arcangelo Morizio, Antonella Argentiero, Endrit Shahini, Max Bittrich · 2023 · Biomedicines
From gene modules to gene markers: an integrated AI-human approach selects CD38 to represent plasma cell-associated transcriptional signatures
Basirudeen Syed Ahamed Kabeer, Bishesh Subba, Darawan Rinchai, Mohammed Toufiq, Taushif Khan, Marina Yurieva, Damien Chaussabel · 2025 · Frontiers in Medicine
Diagnostic Advances in Multiple Myeloma
Kevin M. Barley, Ajai Chari · 2016 · Current Hematologic Malignancy Reports
Orphan drug approvals of 2015: Europe and the United States
Peter Norman · 2016 · Expert Opinion on Orphan Drugs
Triplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities
Agne Paner, Tochukwu M. Okwuosa, Kristin J. Richardson, Edward N. Libby · 2018 · Expert Review of Hematology
Validation and cost-effectiveness of an in-house dithiothreitol (DTT) treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals
Mariam Youssef, Christine Arnesen, Cindy Arledge, Connie Langley, Danielle Sylvester, James Sikora, Marisa B. Marques, X. Long Zheng, Lance A. Williams · 2019 · Transfusion and Apheresis Science
Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms
Lisa Xingguang Lee, Ping Zhou, Cindy Varga, Teresa Fogaren, Katelynn Ho, Xun Ma, Melissa T. Warner, Denis Toskic, Adin Kugelmass, Raymond L. Comenzo · 2019 · Amyloid
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
Shinsuke Iida, Takayuki Ishikawa, Chang‐Ki Min, Kihyun Kım, Su Peng Yeh, Saad Z. Usmani, María‐Victoria Mateos, Hareth Nahi, Christoph Johann Heuck, Xiang Qin et al. · 2021 · Annals of Hematology
Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis
Niels van Nieuwenhuijzen, Rowan Frunt, Anne Maria May, Monique C. Minnema · 2021 · Blood Cancer Journal
Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells
Natalie Baum, Marie Eggers, Julia Koenigsdorf, Stephan Menzel, Julia Hambach, Tobias Stähler, Ralf Fliegert, Frederike Kulow, Gerhard Adam, Friedrich Haag et al. · 2021 · Frontiers in Immunology
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database
Richard LeBlanc, Hira S. Mian, Donna Ellen Reece, Esther Masih‐Khan, Moustafa Kardjadj, Victor Hugo Jimenez-Zepeda, Arleigh B. Robertson McCurdy, Kevin Song, Michaël Sébag, Martha Louzada et al. · 2022 · British Journal of Haematology
A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021
Hanyi Ding, Xiaoyuan Zhang, Dongxu Gang, Xiaoyu He, Songfu Jiang · 2022 · Translational Cancer Research
PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective
Qīng Wáng, Xindi Zhang, Weijun Wei, Min Cao · 2022 · Molecular Pharmaceutics
CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas
Van Anh Ta, Maxime Battistella, Lin‐Pierre Zhao, Gábor Dobos, Caroline Ram‐Wolff, Isabelle Madelaine, Jean-Christophe Bories, Olivier Tournilhac, Jacques Rouanet, Richard Veyrat‐Masson et al. · 2023 · Journal of Investigative Dermatology
Multiple Myeloma and Related Disorders
S. Vincent Rajkumar, Angela A. Dispenzieri · 2020 · Elsevier eBooks
Treatment options for relapse after autograft in multiple myeloma – report from an EBMT educational meeting
Laurent Garderet, Gordon Cook, Holger W. Auner, Benedetto Bruno, Henk M. Lokhorst, José Antonio Pérez‐Simón, Firoozeh Sahebi, Christof Scheid, Curly Morris, Anja van Biezen et al. · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
Elotuzumab as a novel anti-myeloma immunotherapy
Sabarinath Venniyil Radhakrishnan, Neelam Bhardwaj, Mary Nicole Steinbach, Janet Weidner, Tim Luetkens, Djordje Atanackovic · 2017 · Human Vaccines & Immunotherapeutics
Extending shelf life of dithiothreitol‐treated panel RBC s to 28 days
Joerg‐Peter Sigle, B. Mihm, R. Suna, Mario J. Bargetzi · 2018 · Vox Sanguinis
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
on behalf of the European Myeloma Network, Teresa Caballero‐Velázquez, Cristina Calderón‐Cabrera, Lucía López‐Corral, Noemí Puig, Francisco José Márquez-Malaver, Estefanía Pérez‐López, Clara Beatriz García-Calderón, Clara María Rosso-Fernández, Dolores M. Caballero et al. · 2019 · Bone Marrow Transplantation
Multiple Myeloma in a Young Female Presenting with Neurological Symptoms
Matthew H. Lee, Xinmin Zhang, Vinh Nghi Nguyen, Monique A. Hartley-Brown · 2020 · Case Reports in Hematology
Daratumumab for quick and sustained remission in post-transplant relapsed/refractory acute lymphoblastic leukemia
Yongping Zhang, Song Xue, Fuhong Liu, Jingbo Wang · 2020 · Leukemia Research
Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas
David Fernando Moreno, Victòria Clapés, Alfons Soler, Yolanda González Montes, Mercedes Gironella, Cristina Motlló, Miquel Granell, Eugènia Abella, Marta García‐Pintos, Antoni García‐Guiñón et al. · 2022 · Clinical Lymphoma Myeloma & Leukemia
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
Tracy King, Jacqueline Jagger, Jodie Wood, Carmel Woodrow, Alicia Snowden, Sally Haines, Christina Crosbie, Kristen Houdyk · 2018 · Asia-Pacific Journal of Oncology Nursing
Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
Masuho Saburi, Masao Ogata, Yasuhiro Soga, Yoshiyuki Kondo, Ryo Kurimoto, Kazuhito Itani, Kazuhiro Kohno, Hiroki Uchida, Toshiyuki Nakayama · 2020 · Journal of the Japan Society of the Reticuloendothelial System
A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab
Xiaolin Yun, Yingying Zhou, Danna Wu, Yuanbo Liu, Qiongshi Wu · 2024 · Expert Opinion on Drug Safety
Clinical and immunological characteristics of high-risk double-hit multiple myeloma
Yufeng Shang, Guopeng Chen, Li Liu, Ruiyang Pan, Xinqi Li, Hui Shen, Yuxin Tan, Linlu Ma, Xiqin Tong, Weida Wang et al. · 2024 · BMC Cancer
Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study
Zhiliang Guo, Rula Sa, Daqiang Zhao, Songxia Li, Hui Guo, Lan Zhu, Gang Chen · 2025 · BMC Nephrology
New developments in the treatment of multiple myeloma – clinical utility of daratumumab
Cian McEllistrim, Janusz Krawczyk, Michael E O'Dwyer · 2017 · Biologics
Daudi cell stroma: An alternative to dithiothreitol to resolve daratumumab interference in pretransfusion testing
Tony Tremblay, Donald R. Branch, Lionel Loubaki · 2020 · Transfusion
Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma
Ashley Del Dosso, Elizabeth Tadevosyan, James R. Berenson · 2024 · Oncotarget
Personalized Treatment of Multiple Myeloma in Frail Patients
Jodi J. Lipof, Nadine H. Abdallah, Brea C. Lipe · 2024 · Current Oncology Reports
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis
Muhammad Osama, Muhammad Haris Khan, Safeena Khan, Amna Hussain, Ammara Tahir, Mehran Ullah, Abdullah Afridi, Ubaid Ullah, Wajeeh Ur Rehman · 2025 · Therapeutic Advances in Hematology
Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China
Jin Lu, Jian Hou, Kai‐Yan Liu, Simrit Parmar, Adolfo de la Fuente, B Andersson, Chen‐Hua Yan, Daobin Zhou, Daryl Chen Lung Tan, David Ritchie et al. · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
Monoclonal Antibodies for the Treatment of Myeloma
Sagar Lonial · 2016 · The Cancer Journal
A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma
Aneta Schieferdecker, Anna Oberle, Benjamin Thiele, Fabian Hofmann, Markus Göthel, Sebastian Miethe, Michael Hust, Friederike Braig, Mareike Voigt, Ute‐Marie von Pein et al. · 2016 · Blood
Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case‐based approach
Marc‐Andrea Baertsch, Michael Hundemer, Jens Hillengaß, Hartmut Goldschmidt, Marc Steffen Raab · 2017 · Hematological Oncology
Thirty‐three‐day storage of dithiothreitol‐treated red blood cells used to eliminate daratumumab interference in serological testing
Henriette Lorenzen, Nazia Akhtar, Maria Nielsen, Lea Svendsen, Pernille Andersen · 2018 · Vox Sanguinis
Which factors matter the most? Revisiting and dissecting antibody therapeutic doses
Yu Tang, Xiaobing Li, Yanguang Cao · 2021 · Drug Discovery Today
Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium
Agnieszka Krzywdzińska, Bartosz Puła, Anna Czyż, Beata Krzymieniewska, Jolanta Kiernicka‐Parulska, Anna Mierzwa, Donata Szymczak, Aneta Milanowska, Aleksandra Kiraga, Iwona Kwiecień et al. · 2021 · Diagnostics
Immunoglobulin D Multiple Myeloma: A Rare Variant
Kira N MacDougall, Muhammad Rafay Khan Niazi, Maryam Rehan, Wei Xue, Meekoo Dhar · 2022 · Cureus
Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment
Gianfranco Lapietra, Francesca Fazio, Maria Teresa Petrucci · 2022 · Biomolecules
Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab
Adam Jimenez, Ashley Rose Scholl, Bangchen Wang, Michael Schilke, Eric D. Carlsen · 2024 · Clinical Biochemistry
Immune therapy in multiple myeloma.
Katarina Luptakova, David Avigan · 2015 · PubMed
Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms
Shiyong Li, David L. Jaye, Kyle T. Bradley, Linsheng Zhang, Debra Saxe, George Deeb, Charlie E. Hill, Karen P. Mann · 2017 · Archives of Pathology & Laboratory Medicine
Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma
Mattia D’Agostino, Giulia Gazzera, Giusy Cetani, Sara Bringhen, Mario Boccadoro, Francesca Gay · 2018 · Current Medicinal Chemistry
Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
Margaux Lejeune, Elodie Duray, Matthias Peipp, Béatrice Clemenceau, Frédéric Baron, Yves P. Beguin, Jo Caers · 2021 · Cancers
Esterified derivatives of DHA and EPA increase bortezomib cytotoxicity in human multiple myeloma cells
Jing Chen, Rob Ruijtenbeek, Johan Garssen, Frank A. Redegeld · 2022 · European Journal of Pharmacology
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
Michael W. Schmitt, Angela G. Hückelhoven, Michael Hundemer, Anita Schmitt, Susanne Lipp, Martina Emde, Hans Jürgen Salwender, Mathias Hänel, Katja Christina Weisel, Uta Bertsch et al. · 2016 · Oncotarget
The safety of daratumumab for the treatment of multiple myeloma
María José Cejalvo, Paz Ribas, Javier de la Rubia · 2017 · Expert Opinion on Drug Safety
Utilization Patterns of Single Fraction Radiation Therapy for Multiple Myeloma
Lucas Resende Salgado, Sanders Chang, Meng Ru, Erin L Moshier, Zahra Ghiassi–Nejad, Stanislav Lazarev, William Smith, Marcher Thompson, Kavita Vyas Dharmarajan · 2019 · Clinical Lymphoma Myeloma & Leukemia
Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients
Vikram J. Premkumar, Divaya Bhutani, Suzanne Lentzsch · 2020 · Clinical Lymphoma Myeloma & Leukemia
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma
Lucia Pantani, Annamaria Brioli, Paola Tacchetti, Beatrice Anna Zannetti, Katia Mancuso, Serena Rocchi, Marina Martello, Ilaria Rizzello, Carolina Terragna, Elena Zamagni et al. · 2015 · Expert Review of Hematology
A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma
Li, Hongwen, Li, Jing, Wu, Jiazhuo, Shi, Zhuangzhuang, Gao, Yuyang, Song, Wenting, Li, Jiwei, Li, Zhaoming, Zhang, Mingzhi · 2023 · Cancer Medicine
Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma
Amrita Y. Krishnan, Krina K. Patel, Meera Mohan, Sundar Jagannath, Rubén Niesvizky, Rebecca Wang Silbermann, Ziji Yu, Long Tao, Scott R. P. McDonnell, Deborah T. Berg et al. · 2024 · Blood Neoplasia
Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trial
Jiuliang Zhao, Changsong Lin, Qibing Xie, Qiang Shu, Yang Cui, Hui Luo, Wenqiang Fan, Anbin Huang, Yi Zhao, Zili Fu et al. · 2025 · Signal Transduction and Targeted Therapy
Cancer drugs with high repositioning potential for Alzheimer’s disease
Jad Majeed, Marwan Noel Sabbagh, Min H. Kang, J. Josh Lawrence, Kevin Pruitt, Sarah S. Bacus, Ellie Reyna, Maddy Brown, Boris Decourt · 2023 · Expert Opinion on Emerging Drugs
Autoimmune Diseases and Plasma Cells Dyscrasias: Pathogenetic, Molecular and Prognostic Correlations
Laura Giordano, Rossella Rosaria Cacciola, Paola Barone, Veronica Vecchio, Maria Elisa Nasso, Maria Eugenia Alvaro, Sebastiano Gangemi, Emma Cacciola, Alessandro Allegra · 2024 · Diagnostics
Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma
Weijun Yi, Sebastian A. Dziadowicz, Rachel S. Mangano, Lei Wang, Joseph C McBee, Steven M. Frisch, Lori Hazlehurst, Donald Adjeroh, Gangqing Hu · 2024 · International Journal of Molecular Sciences
Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies
Anna Maria Sureda, Peter Dreger, Michael Russell Bishop, Nicolaus Martin Kröger, David Porter · 2018 · Bone Marrow Transplantation
Immunotherapy: the good, the bad, the ugly, and the really ugly
Donald R. Branch · 2019 · Transfusion
Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses
Justin R. Arnall, Donald C. Moore, Hailey Hill, Sarah Griffin, Maxine K. Mueller, Lesli A. Lavery, Peter Michael Voorhees, Saad Z. Usmani · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer
Navgeet Kaur, Anju Goyal, Rakesh Kumar Sindhu · 2020 · Anti-Cancer Agents in Medicinal Chemistry
Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? – Literature review
Luana Mota Ferreira, Jaderson Lima Cerezer, Mailine Gehrcke · 2020 · Hematology Transfusion and Cell Therapy
Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
Edvan de Queiroz Crusoé, Flávia Cristina Fernandes Pimenta, Ângelo Maiolino, Nelson Siqueira de Castro, Huiling Pei, Damila Cristina Trufelli, Mariana Fernandez, Luciana Barreto Herriot · 2020 · Hematology Transfusion and Cell Therapy
Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review
Abubakar Tauseef, Maryam Zafar, Peter T. Silberstein, Joseph Nahas, Thomas Frederickson, Faith Abodunrin, Anum Abbas, Wafa Arshad, Noman Lateef, Hussain I Rangoonwala et al. · 2022 · Journal of Family Medicine and Primary Care
Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)
Hongmei Jing, Yang Li, Junyuan Qi, Lugui Qiu, Chengcheng Fu, Junmin Li, Min Yang, Ming Qi, Ni Fan, Jia Ji et al. · 2022 · Annals of Hematology
Stimulation of natural killer cells with small molecule inhibitors of CD38 for the treatment of neuroblastoma
Catherine M. Mills, Thomas Zachary Benton, Ivett C. Piña, Megan J. Francis, Leticia Reyes, Nathan G. Dolloff, Yuri K. Peterson, Patrick M. Woster · 2023 · Chemical Science
Monoclonal Antibody Therapy in Multiple Myeloma: Where do we Stand and Where Are We Going?
Sharmilan Thanendrarajan, Faith E. Davies, Gareth John Morgan, Carolina Schinke, Pankaj Mathur, Christoph Johann Heuck, Maurizio Zangari, Joshua Epstein, Shmuel Yaccoby, Niels Weinhold et al. · 2016 · Immunotherapy
Practical Approaches to the Management of Dual Refractory Multiple Myeloma
Hans Chulhee Lee, Tomer Martin Mark, Jatin J. Shah · 2016 · Current Hematologic Malignancy Reports
Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
Muhammad Husnain, Sandra E Kurtin, Nikki Barkett, Irbaz Bin Riaz, Amit Agarwal · 2016 · Case Reports in Oncological Medicine
Risk Stratification, Treatment Selection, and Transplant Eligibility in Multiple Myeloma: A Qualitative Study of the Perspectives and Self-Reported Practices of Oncologists
Thomas William LeBlanc, A. Howson, Wendy Turell, P. Sheldon, Susan C. Locke, Sascha Alexander Tuchman, Cristina Gasparetto, S. Kaura, Zeba Khan, Amy P. Abernethy · 2016 · Current Oncology
Anti-CD38 antibody for refractory acquired hemophilia A
Wei Liu, Jiaying Liu, Feng Xue, Renchi Yang, Lei Zhang · 2023 · Journal of Thrombosis and Haemostasis
Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?
Rachel Elizabeth Cooke, Rachel M. Koldej, David Ritchie · 2019 · Journal of Oncology
Elotuzumab in the Treatment of Relapsed and Refractory Multiple Myeloma
Sebastian Grosicki, Martyna Bednarczyk, Agnieszka Barchnicka, Olga Grosicka · 2021 · Future Oncology
Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient
Hailey Connolly, Ally Watson, Michael A Wynd, Kenneth V. Lieberman, Melissa Chaung, Michael J. Goldstein, Guillermo Hidalgo, Ibrahim Batal, Marlene R. Amoruso, Namrata Gargee Jain · 2025 · Pediatric Transplantation
Effective treatment with daratumumab in post-HSCT refractory immune-mediated cytopenias: a case report and literature review
Xiaoyu Jing, Dongjun Li, Sheng-nan Su, Qingkai Dai, Shuwen Sun, Liang Huang, Yuan Ai, Ju Gao, Yiping Zhu, Jiaqi Ni et al. · 2025 · Frontiers in Immunology
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group
Wenming Chen, Zhen Cai, Chor Sang Chim, Wee Joo Chng, Juan Du, Chengcheng Fu, Wen Gao, Ichiro Hanamura, Jian Mei Hou, Jeffrey Huang et al. · 2025 · Clinical Hematology International
One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection
Raphaël Etiève, Margaux Van Wynsberghe, Steven Grangé, Charlotte Laurent, Mathilde Lemoine, Sophie Candon, Dominique Bertrand, Tristan de Nattes · 2025 · Clinical Kidney Journal
Severe lung injury induced by CD38 monoclonal antibody Daratumumab and bortezomib‐containing regimen in a patient with preexisting interstitial lung disease: a case report and literature review
Meng Chen, Lei Zhao, Fang Yao, Xiang Dong Yang · 2022 · Journal of Clinical Pharmacy and Therapeutics
Cryopreservation and Storage Patterns of Hematopoietic Progenitor Stem Cells for Multiple Myeloma
Cara L. Benjamin, Shreena Desai, Denise L. Pereira, Amer Beitinjaneh, Antonio Jiménez, Mark S. Goodman, Lazaros J. Lekakis, Jay Y. Spiegel, Krishna V. Komanduri, Trent Peng Wang · 2023 · Transfusion and Apheresis Science
Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma
Hyun-Woo Lee, Sangmi Kim, Hyung‐Doo Park · 2024 · Clinical Chemistry and Laboratory Medicine (CCLM)
Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
Francesca Fazio, Luca Franceschini, Valeria Tomarchio, Angela Rago, Mariagrazia Garzia, Luca Cupelli, Velia Bongarzoni, Alessandro Andriani, Svitlana Gumenyuk, Agostino Tafuri et al. · 2022 · eJHaem
Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study
Shebli Atrash, Philippe Thompson‐Leduc, Ming‐Hui Tai, Shuchita Kaila, Kathleen S Gray, Isabelle Ghelerter, Marie‐Hélène Lafeuille, David S. Jayabalan, Patrick Lefèbvre, Adriana Rossi · 2022 · Clinical Lymphoma Myeloma & Leukemia
Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis
Michael Hughes, Suzanne Lentzsch · 2023 · Therapeutics and Clinical Risk Management
Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD
Elba Pascual‐Goñi, Roger Collet‐Vidiella, Clara Tejada‐Illa, Lorena Martín-Aguilar, Marta Caballero‐Ávila, Cinta Lleixà, Silvana Novelli, Jordi López‐Pardo, Albert Esquirol, Anaís Mariscal et al. · 2024 · Journal of Neurology Neurosurgery & Psychiatry
Advances and practical use of monoclonal antibodies in multiple myeloma therapy
Hans Chulhee Lee, Donna M. Weber · 2016 · Hematology
Daratumumab – Hope for Myeloma Patients, a Challenge for Clinical Laboratories
Tomáš Jelı́nek, Martin Kořístka, Zuzana Čermáková, Roman Hájek · 2017 · Klinicka onkologie
Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?
Pellegrino Musto · 2018 · The Oncologist
Infections in Patients with Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies
Asma M. Al-Jasser, Khalid Ahmed Al‐Anazi · 2019 · IntechOpen eBooks